JP2017519027A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519027A5 JP2017519027A5 JP2016575040A JP2016575040A JP2017519027A5 JP 2017519027 A5 JP2017519027 A5 JP 2017519027A5 JP 2016575040 A JP2016575040 A JP 2016575040A JP 2016575040 A JP2016575040 A JP 2016575040A JP 2017519027 A5 JP2017519027 A5 JP 2017519027A5
- Authority
- JP
- Japan
- Prior art keywords
- xrpd
- powder
- pattern
- degrees
- measured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims 19
- 230000005855 radiation Effects 0.000 claims 8
- 239000013078 crystal Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- JLCCNYVTIWRPIZ-NRFANRHFSA-N 6-[(1-acetylpiperidin-4-yl)amino]-n-[(2s)-3-(3,4-dihydro-1h-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide Chemical compound C1CN(C(=O)C)CCC1NC1=CC(C(=O)NC[C@H](O)CN2CC3=CC=CC=C3CC2)=NC=N1 JLCCNYVTIWRPIZ-NRFANRHFSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462016819P | 2014-06-25 | 2014-06-25 | |
| US62/016,819 | 2014-06-25 | ||
| PCT/IB2015/054712 WO2015198229A1 (en) | 2014-06-25 | 2015-06-23 | Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519027A JP2017519027A (ja) | 2017-07-13 |
| JP2017519027A5 true JP2017519027A5 (enExample) | 2018-08-02 |
| JP6559719B2 JP6559719B2 (ja) | 2019-08-14 |
Family
ID=53510948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575040A Expired - Fee Related JP6559719B2 (ja) | 2014-06-25 | 2015-06-23 | （ｓ）−６−（（１−アセチルピペリジン−４−イル）アミノ）−ｎ−（３−（３、４−ジヒドロイソキノリン−２（１ｈ）−イル）−２−ヒドロキシプロピル）ピリミジン−４−カルボキサミドの結晶塩 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9884846B2 (enExample) |
| EP (1) | EP3160958B1 (enExample) |
| JP (1) | JP6559719B2 (enExample) |
| KR (1) | KR102493854B1 (enExample) |
| CN (1) | CN106536511B (enExample) |
| AU (1) | AU2015278728B2 (enExample) |
| BR (1) | BR112016030586B1 (enExample) |
| CA (1) | CA2952567A1 (enExample) |
| CL (1) | CL2016003278A1 (enExample) |
| CR (1) | CR20160598A (enExample) |
| CY (1) | CY1124085T1 (enExample) |
| DK (1) | DK3160958T3 (enExample) |
| DO (1) | DOP2016000333A (enExample) |
| EA (1) | EA032017B1 (enExample) |
| ES (1) | ES2869374T3 (enExample) |
| HR (1) | HRP20210681T1 (enExample) |
| HU (1) | HUE054454T2 (enExample) |
| IL (1) | IL249491A0 (enExample) |
| LT (1) | LT3160958T (enExample) |
| MA (1) | MA40219B1 (enExample) |
| MX (1) | MX2017000134A (enExample) |
| PE (1) | PE20170146A1 (enExample) |
| PH (1) | PH12016502523A1 (enExample) |
| PL (1) | PL3160958T3 (enExample) |
| PT (1) | PT3160958T (enExample) |
| RS (1) | RS61731B1 (enExample) |
| SG (1) | SG11201610709UA (enExample) |
| SI (1) | SI3160958T1 (enExample) |
| SM (1) | SMT202100260T1 (enExample) |
| WO (1) | WO2015198229A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY199894A (en) | 2012-12-21 | 2023-11-27 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
| CA2953572A1 (en) * | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| GB201604030D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604022D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604027D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604031D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604020D0 (en) * | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| UA126349C2 (uk) | 2017-12-13 | 2022-09-21 | Люпін Лімітед | Заміщені біциклічні гетероциклічні сполуки як інгібітори prmt5 |
| US12391695B2 (en) | 2019-06-10 | 2025-08-19 | Lupin Limited | PRMT5 inhibitors |
| KR20220086628A (ko) | 2019-10-22 | 2022-06-23 | 루핀 리미티드 | Prmt5 저해제의 약학적 조합물 |
| WO2021111322A1 (en) | 2019-12-03 | 2021-06-10 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| CN112206218B (zh) * | 2020-10-24 | 2022-08-23 | 迪沙药业集团有限公司 | 一种甲硝唑维生素b6组合物 |
| AU2023327684A1 (en) | 2022-08-15 | 2025-03-20 | Astrazeneca Ab | Mta-cooperative prmt5 inhibitors for use in the treatment of cancer |
| KR102851417B1 (ko) * | 2022-08-16 | 2025-08-28 | 제이투에이치바이오텍 (주) | 피리미딘-4-카복사마이드 화합물의 결정형 및 이를 포함하는 경구용 약학 제제 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| EP0644755B1 (en) | 1992-06-10 | 1997-03-19 | NanoSystems L.L.C. | Surface modified nsaid nanoparticles |
| NZ248813A (en) | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| US9044432B2 (en) * | 2009-12-22 | 2015-06-02 | Ohio State Innovation Foundation | Compositions and methods for cancer detection and treatment |
| CN102199623A (zh) * | 2011-03-22 | 2011-09-28 | 中国科学院遗传与发育生物学研究所 | 蛋白质精氨酸甲基转移酶5的新用途 |
| MY199894A (en) | 2012-12-21 | 2023-11-27 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
-
2015
- 2015-06-23 JP JP2016575040A patent/JP6559719B2/ja not_active Expired - Fee Related
- 2015-06-23 CN CN201580040248.3A patent/CN106536511B/zh not_active Expired - Fee Related
- 2015-06-23 HU HUE15733921A patent/HUE054454T2/hu unknown
- 2015-06-23 HR HRP20210681TT patent/HRP20210681T1/hr unknown
- 2015-06-23 MA MA40219A patent/MA40219B1/fr unknown
- 2015-06-23 BR BR112016030586-8A patent/BR112016030586B1/pt not_active IP Right Cessation
- 2015-06-23 CA CA2952567A patent/CA2952567A1/en not_active Abandoned
- 2015-06-23 WO PCT/IB2015/054712 patent/WO2015198229A1/en not_active Ceased
- 2015-06-23 PL PL15733921T patent/PL3160958T3/pl unknown
- 2015-06-23 PE PE2016002765A patent/PE20170146A1/es not_active Application Discontinuation
- 2015-06-23 ES ES15733921T patent/ES2869374T3/es active Active
- 2015-06-23 SM SM20210260T patent/SMT202100260T1/it unknown
- 2015-06-23 PT PT157339219T patent/PT3160958T/pt unknown
- 2015-06-23 KR KR1020177001796A patent/KR102493854B1/ko active Active
- 2015-06-23 MX MX2017000134A patent/MX2017000134A/es unknown
- 2015-06-23 SG SG11201610709UA patent/SG11201610709UA/en unknown
- 2015-06-23 CR CR20160598A patent/CR20160598A/es unknown
- 2015-06-23 US US15/318,714 patent/US9884846B2/en active Active
- 2015-06-23 AU AU2015278728A patent/AU2015278728B2/en not_active Ceased
- 2015-06-23 SI SI201531556T patent/SI3160958T1/sl unknown
- 2015-06-23 DK DK15733921.9T patent/DK3160958T3/da active
- 2015-06-23 RS RS20210484A patent/RS61731B1/sr unknown
- 2015-06-23 EA EA201692465A patent/EA032017B1/ru not_active IP Right Cessation
- 2015-06-23 LT LTEP15733921.9T patent/LT3160958T/lt unknown
- 2015-06-23 EP EP15733921.9A patent/EP3160958B1/en active Active
-
2016
- 2016-12-11 IL IL249491A patent/IL249491A0/en unknown
- 2016-12-16 PH PH12016502523A patent/PH12016502523A1/en unknown
- 2016-12-21 CL CL2016003278A patent/CL2016003278A1/es unknown
- 2016-12-22 DO DO2016000333A patent/DOP2016000333A/es unknown
-
2017
- 2017-12-13 US US15/840,086 patent/US9981948B2/en active Active
-
2021
- 2021-04-29 CY CY20211100373T patent/CY1124085T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519027A5 (enExample) | ||
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| JP2014527042A5 (enExample) | ||
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| JP2018024682A5 (enExample) | ||
| JP2016528242A5 (enExample) | ||
| NO20083059L (no) | Pyrimidinderivater | |
| JP2015078230A5 (enExample) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| JP2015509536A5 (enExample) | ||
| JP2015145426A5 (enExample) | ||
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| JP2019508440A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2015500331A5 (enExample) | ||
| MX338551B (es) | Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa. | |
| RU2017111590A (ru) | Кристаллические формы 2-(4-(4-этокси-6-оксо-1,6-дигидропиридин-3-ил)-2-фторфенил)-n-(5-(1,1,1-трифтор-2- метилпропан-2-ил)изоксазол-3-ил)ацетамида | |
| JP2012036197A5 (enExample) | ||
| MX2016012451A (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina. | |
| JP2014509653A5 (enExample) | ||
| MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
| JP2016539985A5 (enExample) | ||
| JP2015519396A5 (enExample) |